 | • レポートコード：MRC2305A071 • 出版社/出版日：Transparency Market Research / 2023年3月20日 • レポート形態：英文、PDF、226ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥811,300 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,231,300 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,651,300 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界の放射性医薬品におけるセラノスティクス市場規模が、2023年の30億ドルから2031年に124億ドルとなり、予測期間中に年平均15.1%で成長すると推測されています。本レポートは、放射性医薬品におけるセラノスティクスの世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、放射性同位体別（テクネチウム99、ガリウム68、ヨウ素131、ラジウム223、その他）分析、用途別（腫瘍、心臓病、その他）分析、供給源別（原子炉、サイクロトロン）分析、アプロ―チ別（標的治療薬、コンパニオン診断薬）分析、地域別（アメリカ、ヨーロッパ、その他地域）分析、競争状況など、以下の項目を整理しています。また、Advanced Accelerator Applications (Novartis AG)、Aurobindo Pharma、Bayer AG、Blue Earth Diagnostics (Bracco)、Cardinal Health、Clarity Pharmaceuticals、GE Healthcare、Jubliant Radiopharma、Lantheus Medical Imaging、Navidea Biopharmaceuticals, Inc.、SOFIE、Telix Pharmeceuticalsなど、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の放射性医薬品におけるセラノスティクス市場規模：放射性同位体別 - テクネチウム99の市場規模 - ガリウム6の市場規模 - ヨウ素131の市場規模 - ラジウム22の市場規模 - その他放射性同位体の市場規模 ・世界の放射性医薬品におけるセラノスティクス市場規模：用途別 - 腫瘍における市場規模 - 心臓病における市場規模 - その他における市場規模 ・世界の放射性医薬品におけるセラノスティクス市場規模：供給源別 - 原子炉における市場規模 - サイクロトロにおける市場規模 ・世界の放射性医薬品におけるセラノスティクス市場規模：アプロ―チ別 - 標的治療薬の市場規模 - コンパニオン診断薬の市場規模 ・世界の放射性医薬品におけるセラノスティクス市場規模：地域別 - アメリカの放射性医薬品におけるセラノスティクス市場規模 - ヨーロッパの放射性医薬品におけるセラノスティクス市場規模 - その他地域の放射性医薬品におけるセラノスティクス市場規模 ・競争状況 |
Radiopharmaceutical Theranostics Market – Scope of Report
TMR’s report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.
The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.
Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report
• What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
• What are the opportunities in the global radiopharmaceutical theranostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Radiopharmaceutical Theranostics Market – Research Objectives and Research Approach
The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Key Distribution Strategies
5.3. Pricing Analysis
5.4. Patents on Radiotracers
5.5. Technological Advancements in Radiopharmaceutical Theranostics
5.6. Radiotracer Type – Overview
5.7. COVID-19 Pandemic Impact on Industry
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Radioisotope, 2017-2031
6.3.1. Technetium-99
6.3.2. Gallium-68
6.3.3. Iodine-131
6.3.4. Radium-223
6.3.5. Fluorine-18
6.3.6. Yttrium-90
6.3.7. Lutetium-177
6.3.8. Copper-67 & 64
6.3.9. Samarium-153
6.3.10. Others
6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Source, 2017-2031
8.3.1. Nuclear Reactors
8.3.2. Cyclotrons
8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Approach, 2017-2031
9.3.1. Targeted Therapeutic (Rx)
9.3.2. Companion Diagnostic (DX)
9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
10.3.1. Peptidic
10.3.2. Non-peptidic
10.4. Market Attractiveness Analysis, by Radiotracer Type
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
11.1. Introduction & Definition
11.2. Key Findings/Developments
11.3. Market Value Forecast, by End-user, 2017-2031
11.3.1. Hospitals
11.3.2. Academic & Research Institutes
11.3.3. Others
11.4. Market Attractiveness Analysis, by End-user
12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2017-2031
12.2.1. U.S.
12.2.2. Europe
12.2.3. Rest of the World
12.3. Market Attractiveness Analysis, by Region
13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Radioisotope, 2017-2031
13.2.1. Technetium-99
13.2.2. Gallium-68
13.2.3. Iodine-131
13.2.4. Radium-223
13.2.5. Fluorine-18
13.2.6. Yttrium-90
13.2.7. Lutetium-177
13.2.8. Copper-67 & 64
13.2.9. Samarium-153
13.2.10. Others
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Others
13.4. Market Value Forecast, by Source, 2017-2031
13.4.1. Nuclear Reactors
13.4.2. Cyclotrons
13.5. Market Value Forecast, by Approach, 2017-2031
13.5.1. Targeted Therapeutic (Rx)
13.5.2. Companion Diagnostic (DX)
13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
13.6.1. Peptidic
13.6.2. Non-peptidic
13.7. Market Value Forecast, by End-user, 2017-2031
13.7.1. Hospitals
13.7.2. Academic & Research Institutes
13.7.3. Others
13.8. Market Attractiveness Analysis
13.8.1. By Radioisotope
13.8.2. By Application
13.8.3. By Source
13.8.4. By Approach
13.8.5. By Radiotracer Type
13.8.6. By End-user
14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Radioisotope, 2017-2031
14.2.1. Technetium-99
14.2.2. Gallium-68
14.2.3. Iodine-131
14.2.4. Radium-223
14.2.5. Fluorine-18
14.2.6. Yttrium-90
14.2.7. Lutetium-177
14.2.8. Copper-67 & 64
14.2.9. Samarium-153
14.2.10. Others
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Oncology
14.3.2. Cardiology
14.3.3. Others
14.4. Market Value Forecast, by Source, 2017-2031
14.4.1. Nuclear Reactors
14.4.2. Cyclotrons
14.5. Market Value Forecast, by Approach, 2017-2031
14.5.1. Targeted Therapeutic (Rx)
14.5.2. Companion Diagnostic (DX)
14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
14.6.1. Peptidic
14.6.2. Non-peptidic
14.7. Market Value Forecast, by End-user, 2017-2031
14.7.1. Hospitals
14.7.2. Academic & Research Institutes
14.7.3. Others
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Italy
14.8.5. Spain
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Radioisotope
14.9.2. By Application
14.9.3. By Source
14.9.4. By Approach
14.9.5. By Radiotracer Type
14.9.6. By End-user
14.9.7. By Country/Sub-region
15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Radioisotope, 2017-2031
15.2.1. Technetium-99
15.2.2. Gallium-68
15.2.3. Iodine-131
15.2.4. Radium-223
15.2.5. Fluorine-18
15.2.6. Yttrium-90
15.2.7. Lutetium-177
15.2.8. Copper-67 & 64
15.2.9. Samarium-153
15.2.10. Others
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Oncology
15.3.2. Cardiology
15.3.3. Others
15.4. Market Value Forecast, by Source, 2017-2031
15.4.1. Nuclear Reactors
15.4.2. Cyclotrons
15.5. Market Value Forecast, by Approach, 2017-2031
15.5.1. Targeted Therapeutic (Rx)
15.5.2. Companion Diagnostic (DX)
15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
15.6.1. Peptidic
15.6.2. Non-peptidic
15.7. Market Value Forecast, by End-user, 2017-2031
15.7.1. Hospitals
15.7.2. Academic & Research Institutes
15.7.3. Others
15.8. Market Attractiveness Analysis
15.8.1. By Radioisotope
15.8.2. By Application
15.8.3. By Source
15.8.4. By Approach
15.8.5. By Radiotracer Type
15.8.6. By End-user
16. Competition Landscape
16.1. Market Player Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Advanced Accelerator Applications (Novartis AG)
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Aurobindo Pharma
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bayer AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Blue Earth Diagnostics (Bracco)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Cardinal Health
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Clarity Pharmaceuticals
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. GE Healthcare
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Jubliant Radiopharma
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Lantheus Medical Imaging
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Navidea Biopharmaceuticals, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. SOFIE
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Telix Pharmaceuticals
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview